Ekso Bionics® Releases its Upgraded EksoPulse Platform, Advanced Cloud-Based Analytics for Robotic Exoskeleton-Assisted Reha...
February 06 2020 - 08:00AM
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), a leading developer of
robotic exoskeletons, today announced the worldwide launch of
its upgraded EksoPulse platform, an innovative cloud-based
information technology platform that measures and analyzes progress
using the EksoNR robotic exoskeleton. The improved analytics system
provides an easy-to-use dashboard to chart activity in
rehabilitation sessions, enhancing the clinician, institutional,
and patient experience of the most clinically used
exoskeleton.
The new EksoPulse platform technology uniquely allows physical
therapists and physicians to track and personalize patient care
with EksoNR. During rehabilitation sessions, EksoPulse captures
important measures of patient progress, including the number of
steps taken, the quality of steps, and how much assistance was
given to a patient. The data is then synchronized via cellular
technology and transmitted to Ekso’s secure, cloud-based
system.
By logging into the secure EksoPulse portal, clinicians can view
a dashboard and produce reports in order to analyze patient
progress and track changes in patient performance. With this
information, physical therapists and physicians can adjust care
plans, which can have a positive impact on patient care and
recovery.
“As an industry leader, we are committed to innovation and
providing our customers with the latest rehabilitation tools,” said
Jack Peurach, president and chief executive officer of Ekso
Bionics. “By improving our analytics system to offer a
user-friendly dashboard and advanced data analysis, clinicians can
better measure progress and more nimbly adjust care as needed for
better patient outcomes.”
Users can view data stored on the secure EksoPulse system from
any web browser to make informed decisions. Healthcare
administrators can also use the portal to gauge overall usage of
the EksoNR device in their facility.
The upgraded EksoPulse platform is immediately available to
rehabilitation centers around the world that are using the newest
generation EksoNR with SmartAssist, a comprehensive gait therapy
software. EksoGT users will have access to select new EksoPulse
features, and have the option to upgrade to EksoNR, which allows
full access to the new EksoPulse platform.
“The enhanced graphical interface provides more in-depth
information about the overall usage of the device at your center,
as well as data from individual patients. EksoPulse now widens the
ability for management to measure the utilization of its capital
investment in the medical device, in addition to showing individual
progression of each patient for the therapist on the ground,” said
Karen Nolan, Ph.D., Senior Research Scientist, Kessler Foundation.
“It gives therapists better capacity to track and analyze patient
progression in various settings to more effectively challenge
patients in future sessions.”
To learn more about EksoPulse or EksoNR,
visit www.eksobionics.com.
About Ekso Bionics® Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the Company continues to build upon its
industry-leading expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information, visit: www.eksobionics.com or
follow @EksoBionics on Twitter.
About EksoNR EksoNR is the first exoskeleton
cleared by the Food and Drug Administration for use with stroke and
spinal cord injuries from L5 to C7. In Europe, the CE-Mark-cleared
EksoNR allows us to work with patients impacted by all neurological
conditions and lower limb weakness. EksoNR with SmartAssist™
software is the only exoskeleton available for rehabilitation
institutions that can provide adaptive amounts of power to either
side of a patient’s body, challenging the patient as they progress
through their continuum of care. The suit’s patented technology
provides the ability to mobilize patients earlier, more frequently,
and with a greater number of high intensity steps. To date, this
device has helped patients take 115 million steps in over 270
rehabilitation institutions around the world.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) the capacity of
the Company’s products for improving patient care, (iii) the
functionality of the Company’s products and services, and (iv) the
assumptions underlying or relating to any statement described in
points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are
based upon the Company's current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to
a number of risks and uncertainties and other influences, many of
which the Company has no control over. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing to fund the Company's operations and
necessary to develop or enhance its technology and to implement its
business plan and strategies, the significant length of time and
resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market the Company’s products and
services effectively, adverse results in future clinical studies of
the Company's medical device products, the failure to obtain or
maintain patent protection for the Company's technology, failure to
obtain or maintain regulatory approval to market the Company's
medical devices, and existing or increased competition. These and
other factors are identified and described in more detail in the
Company's filings with the SEC. To learn more about Ekso Bionics
please visit us at www.eksobionics.com or follow us on Twitter
at @EksoBionics. The Company does not undertake to update these
forward-looking statements.
Media Contact:Carrie Yamond
Mas917-371-2320cmas@eksobionics.com
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2023 to Mar 2024